GSK Revisits Exec Pay

Houlton, Sarah
February 2004
Pharmaceutical Executive;Feb2004, Vol. 24 Issue 2, p28
Trade Publication
Reports on the plan created by GlaxoSmithKline PLC for compensating senior executives to replace a plan rejected by stockholders in Great Britain. Problem of investors with the original proposal; Changes made to the contracts of other executive directors; Salary and bonus package received by CEO Jean-Pierre Garnier.


Related Articles

  • Fat cat cream goes sour.  // European Chemical News;5/26/2003, Vol. 78 Issue 2054, p5 

    Comments on the decision of GlaxoSmithKline (GSK) shareholders to vote down the proposed remuneration package for chief executive officer Jean-Pierre Garnier. Amount of the proposed package; Argument of shareholders against the proposal; Implication of the GSK vote.

  • Shareholders okay Garnier pay. Beacham, Will // European Chemical News;5/24/2004, Vol. 80 Issue 2101, p9 

    Reports on the approval of the compensation package of Jean-Pierre Garnier, the chief executive officer at GlaxoSmithKline, by shareholders at the British drug group's annual general meeting in May 2004. Value of the compensation package; Potential career changes at the company in 2004 and 2005.

  • Fat-cat salaries are the best way to get the cream. Pitcher, George // Marketing Week;5/29/2003, Vol. 26 Issue 22, p27 

    Focuses on the salary of executives in Great Britain. Increase in the remuneration received by executives in the oil industry as a result of the Iraq conflict; Dissention of the public, especially the press, against the increase in pay received by executives; Issue concerning the proposed pay...

  • EARNING CURVE: MEDICINE.  // Management Today;May2005, p18 

    The article informs about earning of an executive and other staff in the medicare industry. Jean-Pierre Garnier, CEO of pharmaceutical firm GlaxoSmithKline PLC earns £2.4m per annum. A hospital consultant gets a basic pay of £24.6k-£34.5k p.a.

  • GSK makes strides in R&D.  // European Chemical News;12/8/2003, Vol. 79 Issue 2080, p28 

    Reports on the research and development (R&D) achievements of GlaxoSmithKline (GSK) presented by chief executive officer Jean-Pierre Garnier to investors in December 2003. Number of projects in clinical development; Number of chemical entities developed by GSK; R&D innovation launched by the...

  • JP GARNIER. Davidson, Andrew // Management Today;Mar2004, p38 

    The French-born CEO Jean-Pierre Garnier of GlaxoSmithKline PLC has been pilloried for his huge salary demands, but he's not sorry. He and his executives will have earned their high rewards, he insists, if they deliver vital medicines to a world in dire need. Rebuilding its drugs pipeline is...

  • TOP 10 COMPANIES AND THEIR CHIEFS.  // Management Today;Dec2003, p38 

    This article provides information about top 10 companies and their chiefs. some of them are, Sir Terry Leahy, Chief Executive of Tesco PLC. He is with the company since 1979 and ably steering the corporate trolley since March 1997, 47-year-old Leahy has made Tesco's position as the nation's...

  • The human factor. Wheatcroft, Patience // Management Today;Jul2003, p25 

    The article author is of the view that while being the best-paid executive is appreciable, what is not equally appreciable is to benefit mostly from failures. The author illustrates the point with an event involving pharmaceutical company GlaxoSmithKline PLC (GSK). Even though investors of GSK...

  • Start rolling back the CEO options express. Ferlauto, Richard // Pensions & Investments;2/5/2001, Vol. 29 Issue 3, p12 

    Reports the complaint of institutional investors against executive pay packages. Effect of giving excessive equity allocations; List of shareholder agenda for shareholder resolution; Implication of increasing proportion of companies; Impact of increasing severance of pay-off packages for failed...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics